Compare DexCom, Inc. (DXCM) vs PulteGroup, Inc. (PHM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs PulteGroup, Inc. — how do they compare? DexCom, Inc. trades at $84.15 (market cap $31.86B), while PulteGroup, Inc. trades at $112.15 (market cap $21.63B). The key difference: DexCom, Inc. is the larger of the two by market cap, and PulteGroup, Inc. pays a 0.92% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and PulteGroup, Inc. for 91 Days on average.
| DXCM | PHM | |
|---|---|---|
Market Cap | $31.86B | $21.63B |
Volume | 3,607,070 | 2,324,729 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $142.56 |
52-Week Low | $54.84 | $110.11 |
Typical Hold Time | 62 Days | 91 Days |
Enterprise Value | $31.32B | $22.04B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
PulteGroup (PHM) trades at $111.76, down 0.51% amid broader housing sector pressure from rising mortgage rates. The stock shows bearish technical signals with support near $109-110, while fundamentals reveal solid profitability (11.62% net margin) but declining revenue and earnings trends. Recent quarters show mixed earnings performance with two misses and one beat against expectations.
PHM presents a value opportunity with attractive valuation multiples (P/E 11.6) and analyst consensus target of $139.80, but faces headwinds from housing affordability concerns and volatile cash flows. The stock's near-term trajectory depends on Q3 2026 earnings results due October 22, 2026, with institutional ownership remaining stable despite sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About PulteGroup, Inc.
PulteGroup Inc is one of the largest homebuilders in the United States, operating in 40 markets across 23 states. The company mainly builds single-family detached homes (85% of unit sales) and offers products to entry-level, move-up, and active-adult buyers. PulteGroup offers homebuyers mortgage financing and title agency services through its financial services segment. The company is headquartered in Atlanta.
Read more on PHM →
